alpha pharma retatrutide - 20mg Demand for Unapproved Weight-Loss Drug

Knee pain scores dropped 75.8% using the WOMAC pain assessment scale, with 14.1% of patients on the 9mg dose becoming completely pain-free compared to 4.2% on placebo

With an appetite dysregulation, caloric intake is higher than it should be, which is causing a disruption and therefore excess body fat

PRIN: PROGETTI DI RICERCA DI RILEVANTE INTERESSE NAZIONALE / Bando 2022 Prot

SURMOUNT-4 will address the question of weight regain after stopping the drug: patients who took tirzepatide for 6 months, will be assessed for sustained weight loss one year later (NCT04660643)

2010 Geurts L, Neyrinck AM, Delzenne NM, Knauf C, Cani PD